Your browser doesn't support javascript.
loading
Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
Wood, C David; Carvell, Thomas; Gunnell, Andrea; Ojeniyi, Opeoluwa O; Osborne, Cameron; West, Michelle J.
Afiliação
  • Wood CD; School of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
  • Carvell T; School of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
  • Gunnell A; School of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
  • Ojeniyi OO; School of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom.
  • Osborne C; Department of Medical and Molecular Genetics, King's College London School of Medicine, Guy's Hospital, London, United Kingdom.
  • West MJ; School of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom m.j.west@sussex.ac.uk.
J Virol ; 92(19)2018 10 01.
Article em En | MEDLINE | ID: mdl-30021904
ABSTRACT
The oncogenic microRNA (miRNA) miR-155 is the most frequently upregulated miRNA in Epstein-Barr virus (EBV)-positive B cell malignancies and is upregulated in other nonviral lymphomas. Both EBV nuclear antigen 2 (EBNA2) and the B cell transcription factor interferon regulatory factor 4 (IRF4) are known to activate transcription of the host cell gene from which miR-155 is processed (miR-155HG; BIC). EBNA2 also activates IRF4 transcription, indicating that EBV may upregulate miR-155 through direct and indirect mechanisms. The mechanism of transcriptional regulation of IRF4 and miR-155HG by EBNA2, however, has not been defined. We demonstrate that EBNA2 can activate IRF4 and miR-155HG expression through specific upstream enhancers that are dependent on the Notch signaling transcription factor RBPJ, a known binding partner of EBNA2. We demonstrate that in addition to the activation of the miR-155HG promoter, IRF4 can also activate miR-155HG via the upstream enhancer also targeted by EBNA2. Gene editing to remove the EBNA2- and IRF4-responsive miR-155HG enhancer located 60 kb upstream of miR-155HG led to reduced miR-155HG expression in EBV-infected cells. Our data therefore demonstrate that specific RBPJ-dependent enhancers regulate the IRF4-miR-155 expression network and play a key role in the maintenance of miR-155 expression in EBV-infected B cells. These findings provide important insights that will improve our understanding of miR-155 control in B cell malignancies.IMPORTANCE MicroRNA miR-155 is expressed at high levels in many human cancers, particularly lymphomas. Epstein-Barr virus (EBV) infects human B cells and drives the development of numerous lymphomas. Two genes carried by EBV (LMP1 and EBNA2) upregulate miR-155 expression, and miR-155 expression is required for the growth of EBV-infected B cells. We show that the EBV transcription factor EBNA2 upregulates miR-155 expression by activating an enhancer upstream from the miR-155 host gene (miR-155HG) from which miR-155 is derived. We show that EBNA2 also indirectly activates miR-155 expression through enhancer-mediated activation of IRF4 IRF4 then activates both the miR-155HG promoter and the upstream enhancer, independently of EBNA2. Gene editing to remove the miR-155HG enhancer leads to a reduction in miR-155HG expression. We therefore identify enhancer-mediated activation of miR-155HG as a critical step in promoting B cell growth and a likely contributor to lymphoma development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Regulação da Expressão Gênica / Elementos Facilitadores Genéticos / Herpesvirus Humano 4 / Infecções por Vírus Epstein-Barr / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Virol Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Regulação da Expressão Gênica / Elementos Facilitadores Genéticos / Herpesvirus Humano 4 / Infecções por Vírus Epstein-Barr / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Virol Ano de publicação: 2018 Tipo de documento: Article